Ep200: Richard Pops Reflects on a 35-Year Career in Biotech

Episode Summary

Executive Summary: Richard Pops reflects on 35 years leading Alchemies, the company’s evolution from a blood-brain-barrier science project into a profitable neuroscience biopharma, and its late-stage bet on orexin receptor agonists for narcolepsy and beyond. He also discusses policy threats to innovation, the need for a mid-sized biotech voice, and how FDA, pricing, and China shape the industry’s future.

Main Topics: Alchemies’ evolution and long CEO tenure (Priority: 5/5): Pops recounts joining Alchemies at 28, guiding it from a tiny lab focused on brain delivery into a major biotech with proprietary medicines, broad capabilities, and profitability. Orexin biology and sleep medicine breakthrough (Priority: 5/5): The conversation centers on orexin receptor agonists, why the biology matters for wakefulness, and how Alchemies’ elixorexton aims to transform narcolepsy treatment. Clinical differentiation, safety, and efficacy data (Priority: 5/5): Pops explains the clinical signals seen in healthy volunteers and narcolepsy patients, including wakefulness gains, as well as safety concerns around cardiovascular, liver, and visual effects. Commercial expansion beyond narcolepsy (Priority: 4/5): The discussion explores broader uses for orexin agonists in fatigue, ADHD, MS, Parkinson’s, depression, dementia, and other conditions, potentially making the class much larger than a rare-disease drug. Biotech policy, pricing, and the mid-sized company problem (Priority: 5/5): Pops argues that drug pricing reform, IRA/MFN pressure, and reimbursement policy can make profitable mid-sized biotechs unprofitable, motivating the creation of MBAA. FDA process and China competition (Priority: 4/5): He advocates for a back-to-basics PDUFA cycle focused on core review functions and warns that China is now a true innovation competitor, not just a fast follower. Industry culture and long-termism (Priority: 3/5): Pops contrasts biotech’s long development cycle with short-term market pressure, emphasizing mission, talent, and the importance of showing up in policy debates.

Key Arguments: Alchemies succeeded by building capabilities stepwise through partnered products before moving to proprietary medicines and higher-risk novel biology. Orexin deficiency is a clean disease biology in narcolepsy type 1, making orexin agonism a plausible disease-modifying strategy rather than just symptom control. Alchemies’ data suggest orexin agonists can normalize wakefulness and improve cognition/fatigue, supporting potential expansion beyond narcolepsy into larger indications. Safety concerns in the class are real but manageable with improved potency/selectivity; cardiovascular and liver issues seen in earlier compounds have not appeared as major problems for Alchemies’ program. Mid-sized biotechs are uniquely vulnerable to pricing and reimbursement policy because one or two products often determine profitability, unlike diversified big pharma or pre-commercial startups. The biotech ecosystem depends on policy stability, U.S. innovation incentives, and continued basic science leadership to stay ahead of China and sustain discovery. Industry and regulators should prioritize transparent, efficient FDA review and preserve the economic runway needed to fund future medicines.

Data Points: CEO tenure: 35 years - Pops has led Alchemies for 35 years and is among the longest-serving biotech CEOs. Age when named CEO: 28 - He was appointed CEO in 1991 at age 28. Company cash: $1.3 billion - Current cash position mentioned as Alchemies advances late-stage orexin development. Top-line revenue: in excess of $1.5 billion - Pops says proprietary product sales now exceed this level. Rare disease prevalence: ~200,000 U.S. patients - He cites this as the approximate idiopathic hypersomnia / excessive daytime sleepiness candidate pool. Maintenance of wakefulness test baseline: under 5 minutes - NT1 patients in the study had very short baseline wakefulness before treatment. Wakefulness after treatment: above 20 minutes - Orexin agonists raised mean wakefulness latency well beyond existing therapies. Gross-to-net deduction: over 50% - He says Alchemies pays more than half off list price to secure formulary access for an antipsychotic. Part D redesign exposure: 20% of revenues - He says a proposed Part D change would have required manufacturers to pay 20% of revenues to the government. Post-IRA small-molecule exclusivity: 9 years - He references the current U.S. protection period before government negotiation begins. MBAA membership: about 14 companies - He says the Mid-Sized Biotech Alliance of America has roughly 14 member companies. Public company universe studied: 72 companies - He cites an article finding 72 biotech companies with $2B-$10B valuations on a given day in early March. PDUFA review budget share: over 70% user-fee funded - He notes new drug review is largely funded by industry user fees.

Pivotal Quotes: "the world is run by the people who show up" — Richard Pops: On why biotech leaders must engage directly with policymakers rather than assume good outcomes. "we've essentially cured NT1" — physicians exiting the room (as described by Pops): His reaction to the World Sleep meeting data showing dramatic clinical benefit from orexin agonists. "if you do this, here will be the results, and you can see why" — Richard Pops: On how to persuade policymakers by showing company-specific impacts of pricing and reimbursement changes.

Implications: Orexin agonists could redefine sleep medicine and expand into multiple CNS/fatigue indications, but commercialization depends on safety, execution, and a policy environment that preserves incentives for mid-sized biotech innovation.